VistaGen Therapeutics Inc
Research VistaGen Therapeutics Inc (VTGN) on Bullrun: market cap USD 10.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVTGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.65M
- Financial periodFY2026
- RevenueUSD 1.27M
- Revenue growth161.1%
- Net income-USD 69.69M
- Free cash flow-USD 66.59M
Valuation Snapshot
latest market cap is USD 10.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 1.27M | -USD 69.69M | -USD 66.59M | n/a | -1.83 | USD 30.79M | USD 1.04M | USD 35.52M |
| FY2025 | USD 486.00K | -USD 51.42M | -USD 42.29M | n/a | -1.67 | USD 67.13M | USD 1.51M | USD 70.39M |
| FY2024 | USD 1.06M | -USD 29.36M | -USD 25.81M | n/a | -1.52 | USD 119.17M | USD 2.12M | USD 114.29M |
| FY2023 | -USD 227.00K | -USD 59.25M | -USD 50.24M | n/a | -8.51 | USD 16.64M | USD 2.71M | USD 12.08M |
| FY2022 | USD 1.11M | -USD 47.76M | -USD 45.46M | n/a | -7.38 | USD 68.14M | USD 3.04M | USD 64.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 10.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 26.15M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 83.53M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 138.90M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 20.68M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 402.69M | n/a | n/a | n/a |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VistaGen Therapeutics Inc's market cap?
VistaGen Therapeutics Inc's market capitalization is USD 10.65M.
What does VistaGen Therapeutics Inc do?
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.